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Abstract: 
Introduction: Peptic ulcer is a disease which is unrelated to non-steroidal anti-inflammatory drugs (NSAIDs) or 
Helicobacter pylori infection. The higher risk of bleeding and ulcer recurrence highlights the clinical importance of 
analyzing the changing trends of peptic ulcer disease in developing countries. 
Aims:  To assess the proportion of non-NSAID, non-H. pylori peptic ulcer disease in a Pakistani cohort of patients 
with peptic ulcer disease managed at Mayo Hospital Lahore; and to compare the gastric and duodenal ulcer 
subgroups in these patients. 
Methods: The methods that we have used needed patients who had been diagnosed with peptic ulcer disease to be 
screened for a history of NSAID use and after the screening of those with a negative history were tested for H. pylori 
through combined tests of rapid urease and 14C-urea breath test (UBT). Only the cases which showed negative results 
for these two tests were considered ‘H. pylori-negative’. Serum gastrin was measured in all patients included in the 
study. 
Results: 74 gastric ulcer (GU) and fifty-four duodenal ulcer (DU) patients were included in the study. Of these, thirty-
six patients GU (45.9%) and sixteen patients DU (29.6%) were H. pylori-negative. The proportion of non- NSAID 
and non-H. pylori gastric ulcers was significantly higher than duodenal ulcers (p <0.05). However, patients who 
tested negative for H. pylori did not differ significantly from those who tested positive with regard to age, gender, 
serum gastrin level, and presence of risk factors, like smoking and alcoholism. 
Conclusion: The current study indicates existence of high proportion of non-NSAID, non-H. pylori peptic ulcer 
disease in Pakistani patients. 
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INTRODUCTION: 
Helicobacter pylori (H. pylori) infection and non-
steroidal anti-inflammatory drugs (NSAIDs) have for 
long been considered to be the major etiological 
factors in the causation of peptic ulcer disease. 
However, recent years have witnessed a paradigm 
shift in the epidemiology of peptic ulcer disease. A 
review of medical literature suggests that the 
proportion of H. pylori negative peptic ulcer disease 
has been showing increasing trends in developed 
countries. [1]. Data from North America suggests that 
up to 50% of ulcers are H. pylori negative [2]. H. 
pylori infection is more prevalent in developing 
countries, with some regions recording background 
prevalence close to 100%. However, recent reports 
from different parts of Asia have shown a declining 
trend for H. pylori-associated ulcers [3, 4]. The 
parallel forces of effective eradication and 
improvement in hygiene and living conditions have 
possibly contributed to this decline. The proportion of 
H. pylori-negative, NSAID- negative ulcers has not 
been previously documented in Pakistan. Since H. 
pylori-negative ulcers have been shown to have a 
higher incidence of mortality and recurrent 
bleeding, documenting the proportion of such cases is 
important [5]. In this study, we have estimated the 
proportion of H. pylori-negative NSAID negative 
peptic ulcer cases and have also compared the 
characteristics of patients with gastric ulcer (GU) and 
duodenal ulcer (DU). 
 
METHODS: 
Patient selection: For this single-center cross-
sectional study, we recruited patients aged more than 
18 years old, with at least one site of active gastric or 
duodenal ulcer detected during endoscopy. An ulcer 
was defined as an active mucosal lesion with or 
without scarring, with observable depth and longest 
diameter of ≥0.3 cm as measured by open biopsy 
forceps [6]. Female subjects were included only if they 
either had no child-bearing potential (e.g., surgically 
sterile, post-menopausal), or had a negative urine 
pregnancy test. History of previous gastrointestinal 
(GI) disorders and drug intake were recorded. Patients 
who had consumed NSAID, proton pump inhibitors 
(PPIs), H2-receptor antagonists, bismuth-containing 
cytoprotective agents, or antibiotics within four weeks 
prior to entry in the study were excluded. Other 
exclusion criteria included on-going breast-feeding, 
presence of underlying malignancy, recent history of 
GI bleed (<6 months), past history of peptic 
perforation, pyloric stenosis or any gastric surgery, 
and inability to give informed consent. 
 
Patients satisfying the above mentioned criteria were 
included during the study period from January 2008 
to June 2009. The study was approved by the 
institutional clinical research review committee of our 
hospital. Demographic, clinical, and relevant 
laboratory data were collected after obtaining 
informed consent from each patient included in the 
study. 
 
Diagnosis of Helicobacter pylori: During endoscopy, 
one gastric antral biopsy was obtained for rapid urease 
test (RUT) (Pylotest™, Halifax Research Laboratory, 
Kolkata). The tests were read at room temperature after 
four hours. 
All patients were subsequently subjected to a 14C-urea 
breath test, performed in accordance with the 
manufac- turer’s recommendations (Heliprobe, 
Wedholm Medical, Kibion, Sweden). After an 
overnight fast, patients swal- lowed one capsule of 
HeliCap™ containing 1 μCi 14C- labelled urea with 200 
mL of water. After 10 min, the patients exhaled into 
BreathCard™ which was then inserted into the 
Heliprobe(R) analyzer [7]. The results were obtained on-
site and expressed as positive or negative. 
A patient was considered to be H. pylori-positive if 
either RUT or urea breath test (UBT), or both were 
positive. 
Cases who tested negative for both the tests were 
considered H. pylori-negative. Serum gastrin was 
measured for all patients included in the study by 
chemiluminescent immunoassay (Immulite 2000, 
Siemens, Deerfield, USA). 
 
STATISTICAL ANALYSIS: 
The χ2 test was used for testing association 
between qualitative variables and the ‘t’ test was 
used for quantita- tive variables. Sensitivity and 
specificity of the RUT were calculated against the 
14C-urea breath test. Data were processed and 
analyzed with SPSS (Statistical Package for the 
Social Sciences) version 12.0. A value of p< 0.05 
was considered significant. 
 
RESULTS: 
Of the 192 patients diagnosed with peptic ulcer 
disease during the study period, 128 (mean age 42.3 
[range 18–72] years; 108 men) matched our inclusion 
criteria.  Sixty-  four patients were excluded because 
of various criteria (NSAID intake 14, PPI and/or H2 
receptor antagonist 32, recent GI bleeding 8, gastric 
surgery 6, absence of consent 2, underlying 
malignancy 2). Seventy-four patients (57.8%) had 
gastric and 54 (42.2%) had duodenal ulcers. There 
was no correlation between gender and location of 
ulcer. Serum gastrin levels were comparable in both 
the groups. 
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Table 1 shows the results of RUT and 14C-UBT in 
patients. Out of the 128 patients, 69 (54%) and 66 
(51.6%) patients tested positive for RUT and UBT, 
respectively; while, 12 (17.4%) patients with a 
positive RUT tested negative by UBT and 9 (15.2%) 
patients with a negative RUT tested positive by UBT. 
Compared to UBT, RUT had a sensitivity of 86.4% 
and a specificity of 80.6%. Seventy- eight (60.9%) 
patients tested positive by at least one of the tests and 
were considered to be infected with H. pylori. Of the 
50 (39.1%) patients who were negative for H. pylori, 
34 (68%) had GU and 16 (32%) had duodenal ulcer 
(p< 0.05). Patients who tested negative for H. pylori 
did not differ from those who tested positive with 
regard to age, gender, and presence of risk factors, 
like smoking and alcoholism (Table 2). 
 
DISCUSSION: 
Recent reports show a significant difference in the 
proportion of H. pylori-negative ulcers across 
continents (Table 3) [8–17]. Over the past decade, the 
etiological role of H. pylori has been questioned as the 
primary causative factor in DU [18, 19]. Recent 
studies show an increase in H. pylori-negative peptic 
ulcer disease [20]. A retrospective study by 
Jyotheeswaran et al. from the USA reported an H. 
pylori negativity rate of 61% after exclusion of NSAID 
use in DU patients [2]. Further evidence of this low 
prevalence of H. pylori comes from six large trials 
done in the USA involving more than two thousand 
patients which found as many as 27% DU patients to 
be H. pylori negative [17, 21]. On the contrary, studies 
from Europe reflect a much lower prevalence of 
H.pylori-negative peptic ulcers. A study from 
Northern Italy reported a prevalence of only 8% [22]. 
Arroyo et al. from Spain concluded that peptic ulcer 
disease was still highly associated with H. pylori 
infection, and only 1.6% of all duodenal ulcers and 
4.1% of all GUs were found to be negative for both H. 
pylori and NSAIDs in southern Europe [1]. Reports 
from different parts of Asia show wide variation. The 
reported prevalence of H. pylori- negative peptic ulcer 
ranges from as low as 3% in Japan to as high as 29% 
in Singapore and Pakistan [14, 23–25]; recent reports 
from Hong Kong also stress on the changing 
epidemiology of H. pylori in Asia [16]. 
 
Recent Pakistani data show a significant decline in the 
background prevalence of H. pylori with about 45% 
asymptomatic cases which have been harboring 
infection [26]. This downward trend in prevalence is 
significant because a small decline in the community 
prevalence of H. pylori infection markedly increases 
the proportion of H. pylori- negative ulcers compared 
to H. pylori-positive ulcers, if the total prevalence of 
peptic ulcer disease in the community remains 
unchanged. All prior studies looking at the prevalence 
of H. pylori have reported positivity rates of more than 
80% in peptic ulcer patients [27, 28]. This study is the 
first prospective study to report proportion of NSAID-
negative H. pylori-negative peptic ulcer disease. A 
high proportion of peptic ulcer patients in our study, 
were negative for H. pylori. This not only represents a 
significant epidemiological shift but carries great 
clinical importance, since these ulcers are known to be 
refractory to therapy and possess a relatively high risk 
of complications [5]. 
 
The lack of gender predisposition is in accordance 
with the previous reports [29]. There are a number of 
conflicting reports where idiopathic peptic ulcers (H. 
pylori negative, NSAID negative) have been attributed 
variably to younger as well as older age groups [23, 
30]. Although our study population was relatively 
young, we did not find any association between 
idiopathic ulcers and any particular age group. 
Moreover, conventional risk factors, like smoking and 
alcohol consumption were not different between H. 
pylori-positive and negative groups. 
 
Defining a diagnostic standard has often proved to be 
the stumbling block for studies evaluating H. pylori 
prevalence. It is therefore difficult to compare results 
from different studies using various combinations of 
diagnostic tests. Only the current infection evaluation 
with H. pylori is what we wanted to know in the study 
and hence did not evaluate for antibody against H. 
pylori. Although histopathology and culture for H. 
pylori has been used in previous studies as a gold 
standard; sampling error, inter-observer variability, 
increased cost, and diagnostic delay are significant 
pitfalls associated with it [22, 23]. Consensus report of 
the Maastricht III shows satisfactory diagnostic 
accuracy (>90%) of the RUT [31]. Our aim was to 
increase this further by excluding patients with recent 
intake of antisecretory drugs. The same report has also 
recommended the UBT as the best non-invasive option 
to establish the diagnosis of H. pylori infection with 
94% sensitivity and 95% specificity. Since our focus 
was on documenting H. pylori negativity, we chose 
parallel testing with RUT and 14C-UBT to increase 
sensitivity albeit at the cost of a small proportion of 
false positive tests. Serial testing with RUT and 14C- 
UBT, if applied to our study population, would 
increase the proportion of H. pylori-negative ulcers to 
55.5%. Parallel testing effectively achieved our main 
objective, thereby minimizing the chances of 
overestimation of H. pylori- negative NSAID-negative 
peptic ulcers.
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Table 1: Outcome of rapid urease test and urea breath test in the study population 
  
Total (n= 
128) 
Gastric ulcer 
(n= 74) 
Duodenal ulcer 
(n= 54) 
p-
value 
Both RUT and UBT negative 50 (39.1) 34 (45.9) 16 (29.6) 0.03 
RUT positive and/or UBT positive Isolated 
RUT positive 
12 (9.4) 6 (8.1) 6 (11.1) NS 
Isolated UBT positive 9 (7) 4 (5.4) 5 (9.2) NS 
Both tests positive 57 (44.5) 30 (40.5) 27 (50) NS 
Values are as n (%). RUT: rapid urease test; UBT: urea breath test 
 
Table 2: Distribution of H. pylori positive and negative subjects in gastric and duodenal ulcer groups 
    Total 
(n=128) 
Gastric ulcer (n= 
74) 
Duodenal ulcer 
(n= 54) 
    HP+ve HP−ve HP+ve HP−ve 
  Number 128 (100) 
40 
(54.1) 
34 
(45.9) 
38 (70.4) 16 (29.6) 
Values are as n (%). HP: 
Helicobacter pylori 
Median age 
(years)  
39 45 38 38 45 
Male  108 (84.4) 
33 
(82.5) 
29 
(85.3) 
34 (89.5) 12 (75) 
p= NS between HP-positive and 
HP-negative patients in both GU 
and DU groups 
Smoking 36 (28.1) 12 (30) 
12 
(35.3) 
9 (23.7) 3 (18.7) 
Alcohol 8 (6.2) 2 (5) 4 (11.8) 1 (2.6) 1 (6.2) 
 
Table 3: Prevalence of H. pylori-negative, NSAID-negative ulcers in previously published studies 
Study region Author (Reference) Year Total cases H. pylori and NSAID-negative ulcers (%) 
Australia Borody [8] 1991 302 DU 10 (3) 
 Borody [9] 1992 115 GU 13 (11) 
 Xia [10] 2000 45 GU or DU 17 (38) 
Spain Gisbert [11] 1999 774 DU 6 (1) 
 Arroyo [1] 2004 472 DU, 193 GU 8 (2) DU, 25 (13) GU 
Denmark Bytzer [12] 2001 275 DU 22 (8) 
Italy Oderda [13] 2009 47 DU, 23 GU 23 (49) DU, 6 (26) GU 
Japan Nishikawa [14] 2000 398 GU or DU 5 (1) 
Hong Kong Chan [15] 2001 954 GU or DU 40 (4) 
 Hung [16] 2005 275 DU, 314 GU, 49 GU+DU 49 (18) DU, 63 (20) GU, 8 (16) DU+GU 
USA Jyotheeswaran [2] 1998 160 DU, 145 GU 56 (35) DU, 50 (35) GU 
 Ciociola [17] 1999 2394 DU 657 (27) 
 
The etiopathogenesis of non-NSAID non-H. pylori 
ulcer disease is yet to be established. Whether gastric 
acid hypersecretion is responsible for the 
development of these ulcers is still controversial [20]. 
Spurious use of NSAIDs, cyclo-oxygenase-2 
inhibitors, aspirin, and other anti- platelet agents 
have been implicated as a cause of these “idiopathic 
ulcers”. Other rare causes of non-NSAID non-pylori 
ulcers include cirrhosis, Crohn’s disease, Zollinger-
Ellison syndrome, Behcet’s disease, ischemia, and 
infections, such as Cytomegalovirus and Helicobacter 
heilmannii [20]. Although PPIs are currently used for 
treating these ulcers, data regarding their efficacy is 
lacking. Non-NSAID non-H. pylori ulcers have a 
higher risk of recurrence that is around five times 
more as compared to H. pylori- positive ulcers treated 
with eradication therapy [16]. In a seven-year 
prospective cohort study, the rate of ulcer recurrence 
and complication was significantly higher in H. 
pylori-negative patients compared to those who were 
H. pylori-positive [32]. In the absence of established 
treat- ment protocols, long-term maintenance therapy 
with PPIs is often continued indefinitely, especially in 
elderly patients with multiple comorbidities. 
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Contrary to previous data, our study had more gastric 
ulcers compared to duodenal ulcers. This could be due 
to referral patterns of hospital and a significant number 
of patients excluded due to reasons mentioned earlier. 
Moreover, we have documented in our earlier 
epidemiological study [33], a changing trend in 
relative frequency of GU and DU in with a relatively 
higher proportion of GU. Of the 50 patients diagnosed 
with H. pylori-negative and NSAID-negative peptic 
ulcers in our study, the proportion of GUs were greater 
than duodenal ulcers (34/74 vs. 16/54, p < 0.05). 
Previous studies done in Asian population have also 
shown a trend for higher proportion of non-NSAID, 
non-H. pylori ulcers in the stomach compared to the 
duodenum, but the difference was not significant [16]. 
Although our study uncovers a significant trend in the 
peptic ulcer patients, we were limited by the 
unavailability of ulcer histology, antibody testing, or 
tissue cultures for H. pylori and lack of follow up, all 
of which have the potential of yielding valuable 
information in this growing population of idiopathic 
ulcers. Other notable limitations of our study were the 
relatively small number of patients and lack of gastric 
acid output estimation which would have enabled 
further characterization of our patients. However, 
serum gastrin was used as a surrogate marker of gastric 
acid secretion and the values did not differ 
significantly among the H. pylori-positive and 
negative subgroups. 
 
To conclude, our study shows that the existence of 
high proportion of H. pylori-negative, NSAID-
negative peptic ulcer disease is not confined to 
developed countries. A greater proportion of gastric 
ulcer patients were NSAID-naive and H. pylori 
negative compared to duodenal ulcers. 
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